Oncogenic osteomalacia (OOM), or
tumor-induced osteomalacia, is a
rare disease characterized by renal
phosphate wasting and
osteomalacia. It arises due to the secretion of
fibroblast growth factor 23 (FGF-23) from causative
tumors. Matrix extracellular phosphoglycoprotein (MEPE) is predominantly expressed in odontoblasts, osteoblasts, and osteocytes. Although the presence of MEPE
mRNA has been reported in some OOM
tumors, little is known about the prevalence of MEPE expression in OOM
tumors. In this study, the expression of MEPE and FGF-23 in OOM
tumors was investigated at the transcriptional and translational levels. Eleven causative OOM
tumors were analyzed by quantitative real-time reverse transcription-polymerase chain reaction and immunohistochemistry for MEPE and FGF-23 expression.
Hemangiopericytomas and
giant cell tumors, pathological diagnoses that are common in cases of OOM, were obtained from non-osteomalacic patients and analyzed as controls. The gene expression level of FGF23 and MEPE in OOM
tumors was 10(4)- and 10(5)-times higher, respectively, than in non-OOM
tumors. Immunohistochemical staining revealed that FGF-23
protein was expressed in all OOM
tumors, and MEPE was expressed in 10 out of 11 OOM
tumors. Thus, MEPE expression was common in OOM
tumors, similar to FGF-23. These results indicate that, in addition to the hypophosphatemic effects of FGF-23, MEPE or the MEPE-derived acidic
serine aspartate-rich MEPE-associated motif
peptide may contribute to decreased bone mineralization in OOM patients.